Search
for

    Research

    5 / 181 results

    Community Join

    5 / 1000+ results

      community Does anyone know the chemical formula for pelage pp405?

      in Research/Science  14 upvotes 1 year ago
      The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

      community Don't use PP405 from everychem. it is likely fake.

      in Research/Science  65 upvotes 8 months ago
      PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.

      community P-1075: a BETTER version of Minoxidil

      in Research/Science 5 months ago
      P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

      community If PP405 goes systemic this would be quite catastrophic

      in Research/Science  4 upvotes 1 year ago
      Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

      community PP405 2a study was a safety study. Some rational explaining.

      in Research/Science  22 upvotes 6 months ago
      The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.